Cargando…
Clinical Review: Gene-based therapies for ALI/ARDS: where are we now?
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) confer substantial morbidity and mortality, and have no specific therapy. The accessibility of the distal lung epithelium via the airway route, and the relatively transient nature of ALI/ARDS, suggest that the disease may be amen...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218971/ https://www.ncbi.nlm.nih.gov/pubmed/21699743 http://dx.doi.org/10.1186/cc10216 |
_version_ | 1782216769340964864 |
---|---|
author | Devaney, James Contreras, Maya Laffey, John G |
author_facet | Devaney, James Contreras, Maya Laffey, John G |
author_sort | Devaney, James |
collection | PubMed |
description | Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) confer substantial morbidity and mortality, and have no specific therapy. The accessibility of the distal lung epithelium via the airway route, and the relatively transient nature of ALI/ARDS, suggest that the disease may be amenable to gene-based therapies. Ongoing advances in our understanding of the pathophysiology of ALI/ARDS have revealed multiple therapeutic targets for gene-based approaches. Strategies to enhance or restore lung epithelial and/or endothelial cell function, to strengthen lung defense mechanisms against injury, to speed clearance of infection and to enhance the repair process following ALI/ARDS have all demonstrated promise in preclinical models. Despite three decades of gene therapy research, however, the clinical potential for gene-based approaches to lung diseases including ALI/ARDS remains to be realized. Multiple barriers to effective pulmonary gene therapy exist, including the pulmonary architecture, pulmonary defense mechanisms against inhaled particles, the immunogenicity of viral vectors and the poor transfection efficiency of nonviral delivery methods. Deficits remain in our knowledge regarding the optimal molecular targets for gene-based approaches. Encouragingly, recent progress in overcoming these barriers offers hope for the successful translation of gene-based approaches for ALI/ARDS to the clinical setting. |
format | Online Article Text |
id | pubmed-3218971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32189712012-06-20 Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? Devaney, James Contreras, Maya Laffey, John G Crit Care Review Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) confer substantial morbidity and mortality, and have no specific therapy. The accessibility of the distal lung epithelium via the airway route, and the relatively transient nature of ALI/ARDS, suggest that the disease may be amenable to gene-based therapies. Ongoing advances in our understanding of the pathophysiology of ALI/ARDS have revealed multiple therapeutic targets for gene-based approaches. Strategies to enhance or restore lung epithelial and/or endothelial cell function, to strengthen lung defense mechanisms against injury, to speed clearance of infection and to enhance the repair process following ALI/ARDS have all demonstrated promise in preclinical models. Despite three decades of gene therapy research, however, the clinical potential for gene-based approaches to lung diseases including ALI/ARDS remains to be realized. Multiple barriers to effective pulmonary gene therapy exist, including the pulmonary architecture, pulmonary defense mechanisms against inhaled particles, the immunogenicity of viral vectors and the poor transfection efficiency of nonviral delivery methods. Deficits remain in our knowledge regarding the optimal molecular targets for gene-based approaches. Encouragingly, recent progress in overcoming these barriers offers hope for the successful translation of gene-based approaches for ALI/ARDS to the clinical setting. BioMed Central 2011 2011-06-20 /pmc/articles/PMC3218971/ /pubmed/21699743 http://dx.doi.org/10.1186/cc10216 Text en Copyright ©2011 BioMed Central Ltd |
spellingShingle | Review Devaney, James Contreras, Maya Laffey, John G Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title | Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title_full | Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title_fullStr | Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title_full_unstemmed | Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title_short | Clinical Review: Gene-based therapies for ALI/ARDS: where are we now? |
title_sort | clinical review: gene-based therapies for ali/ards: where are we now? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218971/ https://www.ncbi.nlm.nih.gov/pubmed/21699743 http://dx.doi.org/10.1186/cc10216 |
work_keys_str_mv | AT devaneyjames clinicalreviewgenebasedtherapiesforaliardswherearewenow AT contrerasmaya clinicalreviewgenebasedtherapiesforaliardswherearewenow AT laffeyjohng clinicalreviewgenebasedtherapiesforaliardswherearewenow |